Skip to content

AMBULAPSE STUDY Feasibility Study on Laparoscopic Double-mesh Sacrocolpopexy With or Without Robotic Assistance, in Female Patients Presenting With Symptomatic Pelvic Organ Prolapse, Based on an Outpatient Treatment Model.

Feasibility Study on Laparoscopic Double-mesh Sacrocolpopexy With or Without Robotic Assistance, in Female Patients Presenting With Symptomatic Pelvic Organ Prolapse, Based on an Outpatient Treatment Model.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03764852
Acronym
AMBULAPSE
Enrollment
80
Registered
2018-12-05
Start date
2019-12-14
Completion date
2026-12-31
Last updated
2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Organ Prolapse

Keywords

outpatient

Brief summary

Pelvic organ prolapse is an increasingly common functional disorder which affects approximately 30 to 40% of the female population, 12% of whom have a symptomatic form, with a psychological, physical and social impact. Laparoscopic sacrocolpopexy represents the surgical gold standard for the treatment of this functional disorder. It aims to suspend the vaginal vault by means of a prosthesis. The patient satisfaction rate is evaluated at 94% with low overall complication rate, evaluated at 11%. Pelvic organ prolapse surgery is a common, with an estimated 30,000 procedures carried out in France in 2013 (excluding hysterectomy) (2013 ATIH data), and the number will increase in the future due to increasing life expectancy. 13% of women will undergo this type of procedure. The French General Directorate of Health Care Supply (DGOS) deems outpatient surgery to be the benchmark for surgical activity in all eligible patients, and has expressed the need for recommendations and tools for supporting its development. The rate of outpatient surgery for prolapse remains low in France (6.1%, 2015 ATIH data), while it is 25% in the US and 56% in Denmark. The average duration of hospital stays for DRG N81.2 (first degree uterine prolapse) in 2015 was 3.43 days. These procedures have been the subject of publications concerning outpatient care and involving low numbers of patients, with the exception of the publication by Sinhal which involved 111 patients.

Detailed description

In our study, the investigators propose to evaluate the success rate for outpatient laparoscopic sacrocolpopexy with or without robotic assistance in screened patients. With this aim in mind, the investigators will conduct a national multicenter prospective study including 80 female patients. Successful outpatient treatment is defined by the absence of conventional inpatient admission with 24H after surgery, the indications for admission being a CHUNG Score \< 9, one perioperative complication, postoperative urinary retention requiring reinsertion of a urinary catheter. The outpatient success rate for other surgical techniques such as cholecystectomy or laparoscopic hysterectomy is above 90% in the literature. Envisaging an equivalent rate after laparoscopic sacrocolpopexy, our population size would make it possible to obtain precision +/- 5.3% for estimation of this proportion. The patients are followed up for 1 month with a postoperative visit at 30 days, during which the efficacy of the technique is evaluated using conventional indicators (POP-Q; ICIQ, USP, PFDI-20, PISQ-12, PFIQ-7, etc.). Once completed, this preliminary investigation will make it possible to define a reference value for successful outpatient sacrocolpopexy, which has not yet been published, which may be used as a basis for a larger scale randomized study that would aim to compare the efficacy of outpatient treatment, with conventional inpatient treatment, for efficient patient management

Interventions

PROCEDUREoutpatient laparoscopic

The intervention is a outpatient laparoscopic sacrocolpopexy with robotic assistance.

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* woman between 40 and 80 years old * Patient with significant prolapse POP-Q ≥ 2 * BMI \<30 * ASA score ≤ 2 * sterile ECBU

Exclusion criteria

* Criteria related to the pathology or the organ: * History of pelvic cancer surgery * History of prolapse surgery * History of pelvic irradiation * Laying a concomitant urethral strip * Cervico-vaginal smear test not up to date. * Patient pregnant or having a desire for pregnancy * Criteria related to concomitant treatments: * Cefazoline allergy * Taking the following medications within 48 hours * Plavix® * Vitamin K / Low Molecular Weight Healing Heparin * Contraindication to ambulatory care for medical reasons * Sleep apnea syndrome * Cardiopulmonary pathology * Psychiatric pathology * Hemorrhagic risk * Diabetes imbalanced * Unbalanced Hypertension

Design outcomes

Primary

MeasureTime frameDescription
Successful outpatient treatment24 hours after surgerySuccessful outpatient treatment is defined by the absence of conventional inpatient admission with 24H after surgery, the indications for admission being a CHUNG Score \< 9, one perioperative complication, postoperative urinary retention requiring reinsertion of a urinary catheter

Secondary

MeasureTime frameDescription
The percentage of failure of the outpatient24 hours after surgeryThe percentage of failure of the outpatient is defined by the number of patients with a CHUNG score \<9 in the outpatient department that does not allow the discharge of the patient or her admission to conventional hospitalization.

Countries

France

Contacts

Primary ContactBrannwel TIBI, MD
tibi.b@chu-nice.fr0492037849
Backup ContactMatthieu DURAND, MD
durand.m@chu-nice.fr0492037849

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026